Safety Information
Mounjaro Side Effects Explained
Quick Answer: Mounjaro (tirzepatide) most commonly causes nausea, vomiting, diarrhoea, constipation and reduced appetite, particularly during dose escalation. Most side effects are mild to moderate and improve as the body adapts to each new dose level. Serious side effects are rare but include pancreatitis and gallbladder disease.~40%of patients report nausea on Mounjaro
4–8 wksfor most GI side effects to ease significantly
15 mgmaximum maintenance dose — when symptoms most settle
Why Side Effects Happen
Why Does Mounjaro Cause Side Effects?
Most side effects are a direct consequence of Mounjaro's dual GLP-1 and GIP mechanism — not a sign something is wrong. When tirzepatide activates GLP-1 receptors throughout the gastrointestinal tract, it slows gastric emptying, which commonly produces nausea, bloating and discomfort. The GIP receptor co-agonism adds a complementary appetite-suppressing effect but also contributes to dose-dependent side effects. Crucially, each dose increase temporarily raises GI receptor stimulation before adaptation occurs — which is why symptoms peak in the first 1–2 weeks of each dose step then ease.
Common Side Effects (SURMOUNT-1 Trial Data)
Week-by-Week Side Effects Timeline
Managing Nausea on Mounjaro
The most effective single intervention is eating smaller, more frequent meals. Large meals distend the stomach against the backdrop of slowed gastric emptying. Aim for three to four small meals daily rather than one or two larger ones.
Serious Side Effects — Warning Signs
| Side Effect | Frequency | Typical Onset |
|---|---|---|
| Nausea | ~40% | Weeks 1–4 and at each dose step |
| Reduced appetite | ~28% | Within first 2 weeks |
| Diarrhoea | ~23% | Weeks 1–6 |
| Vomiting | ~20% | Weeks 1–4 |
| Constipation | ~17% | Weeks 2–8 |
| Abdominal pain | ~14% | Weeks 1–8 |
| Headache | ~11% | Weeks 1–4 |
| Indigestion | ~10% | Variable |
| Fatigue | ~9% | Weeks 1–6 |
| Dizziness | ~7% | Variable |
| Period | What to Expect |
|---|---|
| Weeks 1–4 (2.5 mg) | Starting dose — mild nausea is common; appetite begins to reduce. Most patients find this dose well tolerated. |
| Weeks 5–8 (5 mg) | First escalation. Nausea may increase temporarily. Diarrhoea is common. Headache and fatigue possible. |
| Weeks 9–12 (7.5 mg) | Peak nausea period for most patients. Constipation may emerge. Appetite suppression is well established. |
| Weeks 13–16 (10 mg) | GI symptoms begin to settle. Significant weight loss acceleration common. |
| Weeks 17–20 (12.5 mg) | Nausea reducing further. Body is well adapted to dual agonism. |
| Week 21+ (15 mg) | Maximum maintenance dose. Side effects substantially reduced for most patients. |
💧 Hydration & Foods
Aim for 1.5–2 litres of water daily. Ginger and peppermint tea can help. Choose plain, easily digestible foods during flare-ups. Avoid fatty, spiced or heavily processed foods especially at each new dose step.
💉 Injection Timing
Some patients inject in the evening so peak side effects occur overnight. Consistency in day and time matters more than the specific choice — select a schedule that can be maintained reliably week to week.
Seek urgent medical attention if you experience any of the following
| Symptom | Action |
|---|---|
| Severe abdominal pain radiating to the back | Seek urgent attention — possible pancreatitis. Stop Mounjaro. |
| Upper right abdominal pain after eating | Contact GP — possible gallbladder issue |
| Swelling of face, lips or throat; difficulty breathing | Call 999 immediately — severe allergic reaction |
| Signs of dehydration (dizziness, dark urine) | Seek medical attention and increase fluids |
| New or worsening mood changes or depression | Contact your GP or mental health professional |
Happy Pharmacy Clinical Support: All Happy Pharmacy patients have access to clinical support throughout treatment. Our pharmacists are available to advise on side effect management, dose adjustments and when to seek further medical review.
FAQs
Frequently Asked Questions: Mounjaro Side Effects
The most common Mounjaro side effects are nausea (~40%), reduced appetite (~28%), diarrhoea (~23%), vomiting (~20%) and constipation (~17%). These arise because tirzepatide's dual GLP-1/GIP mechanism slows gastric emptying and activates receptors throughout the gut. Most ease significantly within four to eight weeks and at the maintenance dose.
Side effects are most frequent during dose escalation, particularly at the 7.5 mg and 10 mg steps where GI receptor stimulation is near-maximum before full adaptation. The 2.5 mg starting dose is best tolerated, and the 15 mg maintenance dose is typically better tolerated than mid-escalation steps as the body has had 20 weeks to adapt.
Nausea is most common in the first one to two weeks at each new dose step, then eases as the body adapts. By the maintenance phase at 15 mg, most patients report that nausea has resolved or occurs only occasionally. Dietary strategies — smaller meals, avoiding fatty foods, staying hydrated — significantly reduce nausea during the adjustment period.
Despite producing greater weight loss, Mounjaro's nausea rates are broadly comparable to Wegovy rather than higher — nausea affects approximately 40% on Mounjaro versus 44% on Wegovy at respective maintenance doses. Some research suggests Mounjaro's GIP co-agonism may partially mitigate nausea relative to pure GLP-1 stimulation at equivalent therapeutic levels.
A small proportion of patients notice temporary hair thinning. This is primarily attributed to rapid weight loss and calorie restriction (telogen effluvium) rather than tirzepatide directly. Hair growth typically returns within six months without specific treatment.
Yes — spending six or eight weeks at each dose step rather than four gives the body more time to adapt and typically reduces side effect severity. This is a recognised clinical approach for patients who find the standard escalation schedule difficult to tolerate. Discuss a modified schedule with your Happy Pharmacy prescribing team before adjusting.
Ready to Start Mounjaro Treatment?
GPhC-registered pharmacy (No. 9012585) · UK-licensed prescribers · Free online assessment
Check Your Eligibility →
Jastreboff AM et al. SURMOUNT-1. N Engl J Med. 2022;387:205–216. Mounjaro SmPC. Eli Lilly. 2023. NICE TA1026. 2024. Happy Pharmacy (GPhC No. 9012585). Educational purposes only.